Lara Gross
Allergy & Immunology · Dallas, TXNPI 1811331705
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (58.8%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 43 manufacturers reported payments, led by Alk-abello, Inc at 30.9% of the total. 2025 is the largest year on record at $73,824, more than ten times the $1,758 reported in 2019. Among allergy & immunology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 744 payments — averaging $230.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alk-abello, Inc$53K
- ARS Pharmaceuticals Operations, Inc.$33K
- Sanofi$20K
- Regeneron Healthcare Solutions, Inc.$17K
- Incyte Corporation$12K
- Dermavant Sciences, Inc.$10K
- plus $27K from 37 others
What the payments were for
- Consulting fees$39,53523%
- Speaking & faculty fees$100,69259%
- Travel & lodging$13,3148%
- Food & beverage$17,51110%
- Education$1380%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$171,190 in reported general payments places this provider in the 95th percentile of 336 allergy & immunology providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 13 | $54,903 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 30 | $22,286 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 23 | $20,689 |
| SymbicortBudesonide/Formoterol Fumarate | 15 | $6,966 |
| Qvar RedihalerBeclomethasone Dipropionate | 17 | $6,881 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $6,239 |
| Pulmicort FlexhalerBudesonide | 13 | $4,844 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 29 | $2,960 |
| RyaltrisOlopatadine Hcl/Mometasone | 12 | $2,775 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 23 | $2,615 |
| Montelukast Sodium | 202 | $1,967 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 66 | $1,592 |
| Azelastine Hcl | 41 | $1,398 |
| Mometasone Furoate | 13 | $1,312 |
| Fluticasone Propionate | 40 | $455 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaBreztri Aerosphere, Symbicort, Pulmicort Flexhaler | $5,672 | $34,09658 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $1,266 | $26,92834 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $109 | $6,88117 claims |
| Hikma Pharmaceuticals USARyaltris | $39 | $2,77512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 336 allergy & immunology providers in Texas.
Other allergy & immunology in Dallas
- Richard WassermanDallas$452K
- Matthew FeldmanDallas$410K
- Sonak DaulatDallas$72K
- Joseph WestDallas$39K
- Anil NandaDallas$35K
- Joseph DiazSan Antonio$1.1M
- Lukena KarkhanisSan Antonio$377K
- Paul VigoAustin$304K
- Neha ReshamwalaAustin$303K
- Bobby LanierBenbrook$149K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.